Shares of Nurix Therapeutics (NRIX) plunged 5.13% in intraday trading on Wednesday, as several Wall Street analysts lowered their price targets for the biopharmaceutical company. The stock's decline comes just ahead of the company's scheduled first-quarter earnings report, adding to investor uncertainty.
Multiple financial institutions adjusted their outlook on Nurix Therapeutics. Needham reduced its target price to $27 from $28, while Wells Fargo made a more significant cut, lowering its target to $25 from $32. Oppenheimer also joined the trend, decreasing its price target to $32 from $35, although it maintained an Outperform rating on the shares. Stifel, while keeping its Buy rating, trimmed its target price to $35 from $36.
The series of target price reductions suggests growing caution among analysts regarding Nurix Therapeutics' near-term prospects. Investors appear to be reacting to these adjustments, leading to the sharp decline in stock price. As the company prepares to release its first-quarter results, market participants will be closely watching for any indications of the company's financial health and future outlook that might justify or contradict the recent analyst actions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.